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Abstract
Background: Dysmenorrhea is a common gynecological complaint in adolescent and young females. The purpose
of this study is to assess the efficacy of Shaofu Zhuyu (SFZY) decoctions as treatments for primary dysmenorrhea.
Methods/design: Fifteen (four English, seven Korean, three Chinese, and one Japanese) databases will be searched
from their inception without a language restriction. These include PubMed, AMED, EMBASE, The Cochrane Library,
seven Korean Medical Databases (Korean Studies Information, DBPIA, Oriental Medicine Advanced Searching Integrated
System, Research Information Service System, KoreaMed, The Town Society of Science Technology, and the Korean
National Assembly Library), three Chinese Medical Databases [the Chinese Medical Database (CNKI), Chongqing VIP
Chinese Science and Technology Periodical Database (VIP), and WanFang Database], and one Japanese Database
(J global). Randomized clinical trials (RCTs) included those that examined an SFZY decoction or a modified SFZY
decoction. The control groups include no treatment, placebo, and medication. Trials testing a combination of
SFZY decoction and medication compare to the same medication alone will be also included. Data extraction
and risk of bias assessments will be performed by two independent reviewers. All statistical analyses will be
conducted using Review Manager software (RevMan V.5.3.0). Methodological quality will be assessed with the
Cochrane risk of bias tool.
Discussion: This systematic review will provide a detailed summary of the available evidence testing the effects
of SFZY decoctions for the treatment of primary dysmenorrhea. The review will benefit patients and practitioners
in the fields of traditional and complementary medicine.
Systematic review registration: PROSPERO registration number: CRD42015016386
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Systematic review
Background
Description of the condition
Dysmenorrhea is a common gynecological complaint in
adolescent and young females. Dysmenorrhea is charac-
terized by lower abdominal pain that occurs during
menstruation [1]. Different types of studies have found a
consistently high prevalence of dysmenorrhea in women
of different ages and nationalities with an estimated
prevalence ranging from 45 to 97 % [2]. Ten percent of
these women suffer from symptoms severe enough to ren-
der them incapacitated for 1 to 3 days each menstrual
cycle [3]. Period pain can lead to absences from school or
work [4]. In the USA alone, it was estimated that in the
mid-1980s, 600 million hours were lost from work, which
led to an economic loss of two billion dollars; in today’s
dollars, this figure would be much higher [5].
How the intervention might work
The mechanisms of primary dysmenorrhea have been at-
tributed to high serum levels of prostaglandin E2 (PGE2),
prostaglandin F2-α (PGF2-α), and leukotriene [6]. Severe
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myometrial contractions, vasoconstriction, uterine ische-
mia, and subsequent dysmenorrheic pain result from the
release of these cytokines. Moreover, withdrawal of pro-
gesterone before the beginning of the menstrual cycle
initiates arachidonic acid release and further elevates cyto-
kine levels due to the degradation of arachidonic acid.
Higher cytokine levels contribute to a higher intensity of
dysmenorrheic pain and associated symptoms [7]. Non-
steroid anti-inflammatory drugs (NSAIDs), therefore, are
the primary treatment for this condition but are limited
by inadequate pain control, gastrointestinal discomfort,
and an impact on renal function. Combined oral con-
traceptives are also frequently used but are not universally
accepted possibly due to their potential side effects includ-
ing inducing endometriosis [8]. Therefore, complementary
and alternative medicine (CAM) is in high demand in
many countries [9]. In one large study, as many as 48 % of
women reported the use of CAM as an alternative to pre-
scription medication or to enhance the effectiveness of
their prescription medications [10, 11]. Recenlty, it was
reported that Shaofu Zhuyu (SFZY) decoction have the
efficacy of uterine smooth muscle constriction and mani-
fested an anti-inflammatory efficacy [12]. Also, SFZY
decoction improved hemorheological factor of blood stasis
and regulation for activity on rat ovary [13].
Description of the intervention
Herbal medicine is currently used in hospitals and clinics
in Korea [14], China [2], Taiwan [15], and Japan [16] for
the treatment of primary dysmenorrhea. SFZY decoction
was first described in the Yi Lin Gai Cuo, which is a fam-
ous formula that has been used for treating primary dys-
menorrhea in China since the Qing dynasty. This
decoction is used, particularly in gynecology, for blood
stasis accompanied by masses and gatherings in the lower
abdomen [17]. Clinically, it has been used for the treat-
ment of chronic pelvic inflammatory disease, infertility,
endometrial hyperplasia, myoma uteri, and uterine cancer
[18]. Many reports have described its efficacy for treating
vascular disorders and pain [19], endometriosis [20], cancer
[21], and menstrual irregularities in vivo [22]. SFZY
decoction composed of ten herbs by Quin-ren Wang in
Qing dynasty: Fructus Foeniculi, Zingiberis Rhizoma,
Cinnamomi Cortex, Paeoniae Rubra Radix, Angelica
Sinensis Radix, Carthami Flos, Myrrha, Corydalis Rhizoma,
Typhae Pollen, and Trogopterori Faeces, in the ratio of
0.5:1:1:1:3:1:1:1:3:2 on a dry weight basis [12]. The detail of
composition is shown Table 1. The composition of China
came from Qing dynasty and decoction of Korean came
from DongUiBoGam. SFZY decoctions have shown an
effect on uterine muscles and may help to prevent and cure
dysmenorrhea. SFZY decoctions are considered an ef-
fective prescription for treating primary dysmenorrhea
[23], which has been reported as one of the most com-
mon gynecological disorders in young women [24].
Why is performing this review important?
Recently, many studies have reported treatments using
herbal formulas. The Cochrane Review on Chinese
herbal medicine showed promising evidence for the
use of Traditional Chinese Medicine (TCM) in reducing
menstrual pain in primary dysmenorrhea. Unfortunately,
many of the studies supporting the use of Chinese herbs
were of poor quality [25, 26].
Currently, no relevant systematic reviews of the efficacy
of SFZY decoctions for treating primary dysmenorrhea
are conducted.
Objectives
The aim of this study is to systematically review the avail-
able literature regarding the efficacy of SFZY decoctions
in treating primary dysmenorrhea.
Methods/design
This study has been registered with international Pro-
spective Register of Systematic Reviews (PROSPERO):
CRD42015016386.
Criteria for including studies in this review
Type of studies
Only randomized controlled trials (RCTs) and quasi-RCTs
will be included.
Type of participants
This study will include women of reproductive age with pri-
mary dysmenorrhea, i.e., individuals with no identifiable
Table 1 Compositions of Shaofu Zhuyu decoction
Name of herbs Scientific name Amount (g)
Chinaa Modifyb Koreac
Foeniculi Fructus Foeniculum vulgare Mill. 0.5 0.5 4.0
Zingiberis Rhizoma Zingiber officinale Roscoe 1.0 1 0.8




Angelicae Sinens Radix Angelica gigas N. 3.0 3 12.0
Cnidii Rhizoma Cnidium officinale
Makino
1.0 1 4.0
Cinnammomi Cortex Cinnamomum loureirii
Nees
1.0 1 4.0
Paeoniae Rubra Radix Paeonia obovata Maxim 1.0 2 8.0
Typhae Pollen Typha angustifolia L. 3.0 1 12.0
Trogopterori Faeces Trogopterus xanthipes 2.0 3 8.0
aQing-ren Wang, “Correction of Errors in Medical Classics”
bXiaochen Huang et al., J Chromatogr B Analyt Technol Biomed Life Sci.
2014; 1;962:75–81
cJun Heo, “DongUiBoGam”
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pelvic pathology as indicated by a pelvic examination, ultra-
sound scans and laparoscopy, or women self-reporting a
diagnosis of primary dysmenorrhea.
Types of interventions
Studies that used an SFZY decoction or a modified
SFZY decoction will be included. SFZY decoctions will
include the following ten formulas: Fructus Foeniculi,
Zingiberis Rhizoma, Cinnamomi Cortex, Paeoniae Rubra
Radix, Angelica Sinensis Radix, Carthami Flos, Myrrha,
Corydalis Rhizoma, Typhae Pollen, and Trogopterori
Faeces [17]. Modified SFZY decoction formulas will be
included as well. Modified SFZY decoctions prescribe
according to TCM syndrome differentiation will be ac-
ceptable and be defined by practitioners as adding only
herbs to the original herbs, resulting in nearly the same
actions as the original SFZY decoction. All types of
herbal medicines will be included. There is no limitation
on the number of herbs, administration methods dosage,
or duration of treatment.
Types of comparisons
The control groups will consist of no treatment, placebo,
and medication. Trials examining a combination of SFZY
decoctions and medication will compare to the same
medication alone will be also included.
Outcome measures
Primary outcomes
1. Pain: a reduction in pain (i.e., menstrual pain) that
occurs only during the intervention or occurred as a
result of the intervention, measure by a visual
analogue scale (VAS), other validated scales, or as a
dichotomous outcome.
2. Response rate: an overall reduction in symptoms
(other menstruation-related symptoms) that
occurs only during the intervention or occurred
as a result of the intervention, measure by changes in
dysmenorrhea symptoms and treatment effectiveness,
and is either self-reported, observed, or reported by
other similar measures.
Secondary outcomes
1. Adverse effects: measured by any relevant incidence
and duration of any side effects.
2. Quality of life: measured by a validated scale.
Search methods for identifying the studies
Electronic searches
The following databases will be searched from their incep-
tion: PubMed, AMED, EMBASE, The Cochrane Library,
seven Korean Medical Databases (Korean Studies Infor-
mation, DBPIA, Oriental Medicine Advanced Searching
Integrated System, Research Information Service System,
KoreaMed, The Town Society of Science Technology, and
the Korean National Assembly Library), three Chinese
Medical Databases [the Chinese Medical Database
(CNKI), Chongqing VIP Chinese Science and Technology
Periodical Database (VIP), and WanFang Database], and
one Japanese Database (J global).
Other sources
Studies will also be obtained from the following sources:
– The reference lists of all relevant articles
– Hand searching of department files
– Unpublished conference proceedings relevant to
primary dysmenorrhoea will be reviewed, if available
Search strategy
The strategy for searching the databases is presented in
Tables 2 and 3. Similar search strategies will be applied
for all databases. In addition, the reference lists of all re-
trieved articles will be hand-searched for further relevant
literature. Hard copies of all included articles will be
read in full. Because all of the various databases use for
this study possessed their own subject headings, each
database will be searched independently.
Data collection and analysis
Selection of studies
Two reviewers (HYL and TYC) will review and screen
the titles and abstracts to identify eligible trials ac-
cording to the inclusion criteria. Disagreements will
be resolved by discussion, if necessary, by the arbiter
(MSL). Details of the study selection procedure are
shown in Fig. 1.
Data extraction
All articles will be performed by two authors (HYL and
TYC) who extract data according to pre-defined criteria.
Information such as the participants, interventions, out-
comes, and results will be obtained from each report.
Any disagreement between the two authors will be
resolved by discussion. Another author (MSL) will act as
an arbiter for unresolved disagreements.
Assessment of bias in the included studies
Two authors (HYL and TYC) will assess the risk of bias
using the following seven criteria from the Cochrane clas-
sification: (1) random sequence generation, (2) allocation
concealment, (3) blinding of participants and personnel,
(4) blinding of outcome assessment, (5) incomplete out-
come data, (6) selective outcome reporting, and (7) other
sources of bias (we evaluate baseline imbalance) [27]. This
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review uses “L, U and H” as judgments keys; “Low” indi-
cates a low risk of bias (L), “Unclear” indicates that the
risk of bias is uncertain (U), and “High” indicates a high
risk of bias (H). Disagreements will be resolved by discus-
sions between all reviewers.
Data synthesis
All statistical analyses will be conducted using the
Cochrane Collaboration’s software program, Review
Manager (RevMan), Version 5.3.0 for Windows
(Copenhagen, The Nordic Cochrane Center). Differ-
ences between the intervention and control groups
will be assessed. For the continuous data, we will use
the mean difference (MD) with 95 % confidence in-
tervals (CI) to measure the treatment effect. We will
convert other forms of data into MDs. In the case of
outcome variables with different scales, we will use
the standardized mean difference (SMD) with 95 %
Cis. For dichotomous data, we will present the
treatment effects as a relative risk (RR) with 95 %
Cis. We will convert other binary data into the RR
form. For studies with insufficient information, we
will contact the primary authors to acquire and verify
data when possible. The chi-square test for hetero-
geneity and the I2 test will be used to evaluate the
heterogeneity of the included studies. Unless excessive
statistical heterogeneity is present, we will pool the
data across studies for the meta-analysis using a fixed
effects model.
Unit of analysis issues
For cross-over trials, data from the first treatment period
will be used. For trials in which more than one control
group will be assessed, the primary analysis will combine
the data from each control group. Subgroup analyses of
the control groups will also be performed. Each patient
will be counted only once in the analysis.
Dealing with the missing data
Intention-to-treat analyses that include all of the random-
ized patients will be performed. For patients with missing
outcome data, a carry-forward of the last observed re-
sponse will be used. The individual patient data will be
Table 3 Search strategy used in CNKI
Number Search items
1 Related to intervention 少腹逐瘀汤
2 Shaofu Zhuyu decoction
3 Shaofu Zhuyu formula
4 Shaofu Zhuyu tang
5 1 or 2–5










16 6 or 7–15




21 Randomized controlled trial
22 17 or 18–22
23 6 and 16 and 22
Table 2 Search strategy used in PubMed
Number Search items
1 Related to intervention 少腹逐瘀汤
2 Shaofu Zhuyu decoction
3 Shaofu Zhuyu formula
4 Shaofu Zhuyu tang
5 1 or 2–5








14 7 or 8–14
15 Related to study design Randomized controlled trial







23 #15 OR #16 OR #17 OR #18 OR #19
OR #20 OR #21 OR #22
24 Animals NOT humans
25 #23 NOT #25
Any words containing this searching item will be searched. This search
strategy will be suitable for other electronic databases
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sought from the original source or the published trial re-
ports when the individual patient data are unavailable.
Assessment of heterogeneity
We will use the random effects or fixed effects model
for the meta-analysis according to the data analysis. If
a meta-analysis is possible, we will use the I2 statistic
to quantify the inconsistencies among the included stud-
ies. According to the guidance given in the Cochrane
Handbook for Systematic Reviews of Interventions, as a
general rule, I2 values of up to 25 % provide evidence of
low heterogeneity; a value of 50 % is considered moder-
ate heterogeneity and 75 % or above is considered as a
high heterogeneity. In the presence of significant het-
erogeneity, the causes of heterogeneity will be exam-
ined by pre-specified subgroup analysis and also
sensitivity analysis, if possible. Where subgroup analysis
fails to explain the heterogeneity, then data will be
analyzed using the random effects model. If heterogen-
eity is observed, we will conduct a subgroup analysis to
explore the possible causes [28].
Assessment of reporting biases
If a sufficient number of included studies (at least ten trials)
are available, we will use funnel plots to detect reporting
biases. However, funnel plot asymmetry is not the same as
publication bias; therefore, we will attempt to distinguish
the possible reasons for the asymmetry, such as small-study
effects, poor methodological quality, and true heterogeneity
in the included [29, 30].
Subgroup analysis and investigation of heterogeneity
If there are an adequate number of studies, we will con-
duct subgroup analyses to interpret the heterogeneity
between the studies, including the following:
Fig. 1 PRISMA diagram for the included studies. NRS non-randomized studies, SFZY Shaofu Zhuyu
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1. Type of design: SFZY decoction treatment used
alone or as combination therapy with SFZY
decoction and conventional therapy
2. Type of intervention: type of herbal medicines
(SFZY decoction or modified SFZY decoction)
Sensitivity analysis
We will conduct sensitivity analysis to test the robustness
of the primary decisions of the review process. The princi-
pal decision nodes conclude methodological quality, sample
size and the effect of missing data. The meta-analysis will
be repeated, and studies of lower quality will be excluded.
The result will be compared and discussed according
to the results.
Ethics and dissemination
Ethical approval is not required, given that this protocol
is for a systematic review. The findings of this review
will be disseminated widely through peer-reviewed pub-
lications and conference presentations.
Discussion
As a primary data collection will not be undertaken, no
additional formal ethical assessment or informed consent is
required. The systematic review will be published in a peer-
reviewed journal and disseminated electronically or in print.
Updates of the review will be conducted to inform and
guide healthcare practice and policy. In this review, we will
collect data on the safety and efficacy of SFZY decoctions
for treatment of primary dysmenorrhea. The review will fuel
the development of treatment of primary dysmenorrhea
patients using traditional and complementary medicine.
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